buprenorphine transdermal / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 25 Diseases   17 Trials   17 Trials   675 News 


«12345678910»
  • ||||||||||  buprenorphine transdermal / Generic mfg., methadone / Generic mfg.
    Journal:  Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block. (Pubmed Central) -  Dec 30, 2020   
    QTC prolongation that crosses the 10 msec threshold of regulatory concern was observed at a supratherapeutic dose in two thorough QT studies for the transdermal buprenorphine product BUTRANS®...For comparison, methadone, a MOR agonist associated with QTC prolongation and high TdP risk, and naltrexone and naloxone, two opioid receptor antagonists, were also studied...There is no evidence that buprenorphine use is associated with TdP. Whether this lack of TdP risk can be generalized to other drugs with QTC prolongation not mediated by acute hERG channel block warrants further study.
  • ||||||||||  buprenorphine transdermal / Generic mfg.
    Trial completion date, Trial primary completion date:  Neuroimaging Study on the Effect of Transdermal Buprenorphine in Complex Regional Pain Syndrome Patients (clinicaltrials.gov) -  Oct 22, 2020   
    P=N/A,  N=20, Recruiting, 
    Whether this lack of TdP risk can be generalized to other drugs with QTC prolongation not mediated by acute hERG channel block warrants further study. Trial completion date: Apr 2020 --> Apr 2021 | Trial primary completion date: Feb 2020 --> Feb 2021
  • ||||||||||  buprenorphine transdermal / Generic mfg.
    [VIRTUAL] EFFICACY AND TOLERABILITY OF LOW DOSE BUPRENORPHINE PATCH IN CHRONIC NON-CANCER PAIN PATIENTS PREVIOUSLY TREATED WITH OPIOIDS () -  Aug 30, 2020 - Abstract #WIP2020WIP_500;    
    Objectives: In 2017 low dose buprenorphine transdermal patch(LDBTP) has been introduced in Europe.We report the results of LDBTP application on patients with chronic non- cancer pain who were given LDBTP after having discontinued other opioid medications due to non efficacy or intolerable side effects... LDTBP is a promising alternative to conven- tional opioid treatment, its efficacy and tolerability makes it a valid option for patients with severe chronic pain.Figure 1: Patients investigated with starting dosages and outcome at 1 month follow up
  • ||||||||||  Butrans (buprenorphine transdermal) / Purdue, Mundipharma, Hisamitsu
    Journal:  A dataset for the flood vulnerability assessment of the upper Cross River basin using morphometric analysis. (Pubmed Central) -  Mar 28, 2020   
    The on-site collection of data is not only time consuming, but expensive and perhaps near impossible in restive communities within the upper Cross River basin (UCRB)...The geology map provides confirmatory information to the morphometric analysis. The compound factor computed from all the derived morphometric parameters enhance the determination of the overall flood potential of the congruent sub-basins.
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date:  Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology (clinicaltrials.gov) -  Mar 24, 2020   
    P4,  N=0, Withdrawn, 
    The compound factor computed from all the derived morphometric parameters enhance the determination of the overall flood potential of the congruent sub-basins. N=144 --> 0 | Trial completion date: Sep 2020 --> Mar 2020 | Recruiting --> Withdrawn | Trial primary completion date: Jun 2020 --> Mar 2020
  • ||||||||||  Belbuca (buprenorphine BEMA) / BDSI, Butrans (buprenorphine transdermal) / Purdue, Mundipharma, Hisamitsu
    Is butrans like belbuca? (Twitter) -  Dec 16, 2019   
  • ||||||||||  Butrans (buprenorphine transdermal) / Purdue, Mundipharma, Hisamitsu
    Clinical, Review, Journal:  A Scoping Review of Transdermal Buprenorphine Use for Non-surgical Pain in the Pediatric Population. (Pubmed Central) -  Dec 8, 2019   
    To our knowledge, there are no major studies investigating this subject, and it is our hope that future studies will explore the use of transdermal buprenorphine as an alternative pain management technique in pediatrics. The intent of our scoping review is to highlight the lack of research in this area; therefore, future studies may be conducted to support its use in North America.
  • ||||||||||  buprenorphine transdermal / Generic mfg.
    Trial primary completion date:  Neuroimaging Study on the Effect of Transdermal Buprenorphine in Complex Regional Pain Syndrome Patients (clinicaltrials.gov) -  Sep 18, 2019   
    P=N/A,  N=20, Recruiting, 
    The intent of our scoping review is to highlight the lack of research in this area; therefore, future studies may be conducted to support its use in North America. Trial primary completion date: Aug 2019 --> Feb 2020
  • ||||||||||  Butrans (buprenorphine transdermal) / Purdue, Mundipharma, Hisamitsu
    Journal:  Baerveldt tube shunt implantation through a long scleral tunnel. (Pubmed Central) -  Aug 17, 2019   
    The outcomes were comparable to other reports of Baerveldt glaucoma implant surgery, although the number of cases was limited in this study. A long scleral tunnel can substitute for a preserved scleral patch and self-scleral flap to avoid tube-related complications.
  • ||||||||||  Butrans (buprenorphine transdermal) / Purdue, Mundipharma, Hisamitsu
    Review, Journal:  Transdermal buprenorphine patch: Potential for role in management of opioid dependence. (Pubmed Central) -  Aug 1, 2019   
    This narrative review discusses the transdermal buprenorphine formulations, and its pharmacology, drug interaction and tolerability profile. The studies utilizing buprenorphine transdermal patches in the treatment of opioid dependence are examined, while the potential of using such patches for maintenance treatment of opioid dependence is examined.
  • ||||||||||  buprenorphine transdermal / Generic mfg.
    Enrollment open:  Neuroimaging Study on the Effect of Transdermal Buprenorphine in Complex Regional Pain Syndrome Patients (clinicaltrials.gov) -  Jul 5, 2019   
    P=N/A,  N=20, Recruiting, 
    This novel application of BTDP directly to the painful knee joint of knee OA patients led to a decrease in the NRS score, adverse effects, and an increase in compliance compared with the chest application method. Not yet recruiting --> Recruiting
  • ||||||||||  buprenorphine transdermal / Generic mfg.
    Trial completion date:  Buprenorphine Transdermal Patches in Arthroscopic Rotator Cuff Repair (clinicaltrials.gov) -  Jan 30, 2019   
    P2/3,  N=50, Recruiting, 
    We recommend transdermal buprenorphine or codeine/ibuprofen for pain management during rehabilitation after distal radius fracture stabilized with VLP. Trial completion date: Dec 2018 --> May 2019